UBS Maintains Buy on Celldex Therapeutics, Raises Price Target to $45
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. CLDX | 0.00 |
UBS analyst David Dai maintains Celldex Therapeutics (NASDAQ:
CLDX) with a Buy and raises the price target from $38 to $45.